<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356200</url>
  </required_header>
  <id_info>
    <org_study_id>FP-CL1</org_study_id>
    <nct_id>NCT00356200</nct_id>
  </id_info>
  <brief_title>Fluphenazine Decanoate for Psoriasis</brief_title>
  <official_title>Ascending-Dose, Double-Blind, Placebo-Controlled, Bilateral Study of Intralesional Fluphenazine Decanoate in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Control</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research study to evaluate the effectiveness and safety of fluphenazine
      decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine
      decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have
      schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for
      use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test
      tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a hyperproliferative, inflammatory, immune-mediated skin disease that affects
      approximately 2% of the United States and European populations (Tutrone 2001, Kipnis 2005).
      This disease manifests as red, scaly plaques that are itchy and/or painful. Patients with
      psoriasis may be socially stigmatized because of their appearance. Currently, there is no
      cure for this condition. Often, repeated medical treatments are necessary and can become
      expensive. Treatment with topical corticosteroids is the mainstay therapy for mild to
      moderate psoriasis. In more severe cases, systemic therapies (e.g., cyclosporine) and
      phototherapy (e.g., ultraviolet B (UVB) irradiation) are used. These treatments, however, are
      associated with toxicities or inconvenience. There is anecdotal evidence to suggest that
      antipsychotic drugs have a beneficial effect on psoriasis (Gupta 2001, 2003).

      Fluphenazine is a phenothiazine antipsychotic drug. In vitro, fluphenazine kills activated
      human T cells under conditions that do not affect resting T cells (Immune Control Inc. data
      not shown). To determine the size of a therapeutic window for human peripheral blood
      mononuclear cells (PBMC)s, Immune Control Inc. performed the following experiments. First,
      phytohemagglutinin- (PHA)-activated cells were exposed to 2, 10, or 20 µM fluphenazine for 0,
      18, 24, 36, 48, or 72 hours. Second, resting cells were exposed to identical fluphenazine
      concentrations for identical time periods, after which the drug was washed out of the cells,
      and the cells activated with PHA. In all cases, deoxyribonucleic acid (DNA) synthesis was
      measured by exposing the cells to tritiated thymidine, and measuring the incorporated
      nucleotide by scintillation counting. The data show that exposure of activated cells to 10 µM
      fluphenazine for 72 hours, or 20 µM fluphenazine for 36 hours, caused the death of virtually
      all of the activated cells. The ability of the resting cells to initiate DNA synthesis after
      activation, by contrast, was largely unaffected by these fluphenazine exposures. Although we
      cannot precisely control intralesional fluphenazine concentrations, we expect that injections
      of up to 1 mg fluphenazine decanoate will yield local concentrations that exceed 10 µM
      without significant systemic fluphenazine concentrations.

      We propose that fluphenazine will suppress proliferating T-lymphocytes in psoriatic plaques
      in vivo and thus result in healing of plaques. The objective of this study is to assess the
      safety and biologic activity of intralesional injection of fluphenazine decanoate in adult
      subjects with psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment criteria met
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Target Lesion Score at Week 4 Compared to Baseline</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Change in score from 0-14 of target lesion disease activity based on scaling, erythema, and induration as determined by a physician assessor at week 4 compared to baseline (with 0 being no disease activity and 14 being maximum disease activity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Target Lesion Pruritus Visual Analog Scale (VAS) at Week 4 Compared to Baseline.</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 4 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Fluphenazine treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with fluphenazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treated with Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluphenazine Decanoate</intervention_name>
    <description>Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: &quot;APP Pharmaceuticals&quot; is the name of the pharmaceutical company; APP is not an acronym.</description>
    <arm_group_label>Fluphenazine treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 to 65 years of age with psoriasis, in general good health

          -  Must have symmetric target lesions approximately 2-4 cm in diameter on each side of
             the body (e.g., thighs) with baseline target lesion score of 6 or higher (scale of
             0-12) for each target

          -  Women of childbearing potential must agree to use two forms of contraception for the
             duration of the study

        Exclusion Criteria:

          -  Infliximab (Remicade) or alefacept (Amevive) within the past 6 months (24 weeks)

          -  Etanercept (Enbrel), efalizumab (Raptiva), adalimumab (Humira), or other tumor
             necrosis factor- (TNF)-alpha inhibitor within the past 3 months (12 weeks)

          -  Other systemic psoriasis therapies (e.g., methotrexate, cyclosporine, acitretin) or
             PUVA (psoralen plus ultraviolet A) within the past 4 weeks

          -  Ultraviolet B (UVB) or topical therapy (other than over the counter (OTC) moisturizers
             and shampoos) within the past 2 weeks (including topical corticosteroids, vitamin A
             and D analogues)

          -  Receipt of an investigational agent within the past 4 weeks

          -  Systemic corticosteroid therapy

          -  Inability to understand consent or comply with protocol

          -  Pregnancy, lactation, or unwillingness to use adequate birth control during the study

          -  Impaired hepatic function

          -  Known Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS),
             hepatitis B/C

          -  Blood dyscrasia

          -  Epilepsy

          -  Tardive dyskinesia

          -  Excessive alcohol consumption

          -  Current use of selective serotonin reuptake inhibitors (SSRI), tricyclic, or
             norephinephrine reuptake inhibitor antidepressants or use within 6 weeks of beginning
             the study

          -  Concurrent use of anti-seizure drugs, with the exception of gabapentin for treatment
             of neuropathy

          -  Use of phenothiazine antipsychotics or anticholinergics

          -  Known allergy to fluphenazine decanoate or other phenothiazines

          -  Known allergy to parabens/para-aminobenzoic acid (PABA), benzyl alcohol, sesame oil or
             sesame seeds

          -  Clinically significant mitral valve disease

          -  Clinically significant and uncontrolled cardiovascular disease

          -  QTc &gt;450 msec, or evidence of a clinically significant dysrhythmia on
             electrocardiography (ECG)

          -  Operator of heavy machinery

          -  Pheochromocytoma

          -  History of breast cancer

          -  History of seizure disorder

          -  Occupational exposure to organophosphate insecticides

          -  Parkinson's disease and other related movement disorders

          -  Lab abnormalities including:

          -  Alanine aminotranferease (ALT)/aspartate aminotransferase (AST) ≥ 2X upper limit of
             reference range

          -  Creatinine ≥ 1.5X upper limit of reference range

          -  Bilirubin ≥ 2X upper limit of reference range

          -  Absolute total lymphocyte or polymorphonuclear leucocyte count ≤ 1000/uL or ≥ 3X upper
             limit of ref range

          -  Platelets ≤ 80,000/uL

          -  Hemoglobin ≤ 8.0 g/dL

          -  Glucose ≥ 200 mg/dL

          -  Fasting blood sugar ≥ 126 mg/dL

          -  Concurrent use of drugs listed in Appendix F
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice B Gottlieb, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM. Biologic therapy for psoriasis: a brief history, II. Cutis. 2001 Dec;68(6):367-72. Review.</citation>
    <PMID>11775769</PMID>
  </reference>
  <reference>
    <citation>Kipnis CD, Myers WA, Opeola M, Gottlieb AB. Biologic treatments for psoriasis. J Am Acad Dermatol. 2005 Apr;52(4):671-82.</citation>
    <PMID>15793519</PMID>
  </reference>
  <reference>
    <citation>Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4(12):833-42. Review.</citation>
    <PMID>14640776</PMID>
  </reference>
  <reference>
    <citation>Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. 2001 Nov;15(6):512-8. Review.</citation>
    <PMID>11843209</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <results_first_submitted>November 15, 2010</results_first_submitted>
  <results_first_submitted_qc>December 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2010</results_first_posted>
  <last_update_submitted>December 20, 2010</last_update_submitted>
  <last_update_submitted_qc>December 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alice B Gottlieb, MD, PhD</name_title>
    <organization>Tufts Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluphenazine</mesh_term>
    <mesh_term>Fluphenazine depot</mesh_term>
    <mesh_term>Fluphenazine enanthate</mesh_term>
    <mesh_term>Decanoic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: 10 ug/ml Fluphenazine Decanoate</title>
          <description>Receiving fluphenazine decanoate (10 ug/ml) in a target lesion on one side of the body and placebo in a lesion on the other side of the body.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: 100 ug/ml Fluphenazine Decanoate</title>
          <description>Receiving fluphenazine decanoate (100 ug/ml) in a target lesion on one side of the body and placebo in a lesion on the other side of the body.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort 1: 10 ug/ml</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cohort 2: 100 ug/ml (New Patients)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: 10 ug/ml Fluphenazine Decanoate</title>
          <description>Receiving fluphenazine decanoate (10 ug/ml) in a target lesion on one side of the body and placebo in a lesion on the other side of the body</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: 100 ug/ml Fluphenazine Decanoate</title>
          <description>Receiving fluphenazine decanoate (100 ug/ml) in a target lesion on one side of the body and placebo in a lesion on the other side of the body</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="11.70"/>
                    <measurement group_id="B2" value="38.8" spread="6.69"/>
                    <measurement group_id="B3" value="39.1" spread="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Target Lesion Pruritus Visual Analog Scale (VAS) at Week 4 Compared to Baseline.</title>
        <description>Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 4 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).</description>
        <time_frame>Baseline to week 4</time_frame>
        <population>all 5 patients per cohort completed the visit at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, 10 ug/ml Fluphenazine Treated Lesion</title>
            <description>lesion receiving 10 ug/ml Fluphenazine decanoate (Cohort 1)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Placebo Treated Lesion</title>
            <description>lesion treated with placebo (Cohort 1)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2, 100 ug/ml Fluphenazine Treated Lesion</title>
            <description>lesion receiving 100 ug/ml Fluphenazine decanoate (Cohort 2)</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Placebo Treated Lesion</title>
            <description>lesion treated with placebo (Cohort 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Target Lesion Pruritus Visual Analog Scale (VAS) at Week 4 Compared to Baseline.</title>
          <description>Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 4 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).</description>
          <population>all 5 patients per cohort completed the visit at week 4</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30" spread="35.07"/>
                    <measurement group_id="O2" value="-27.2" spread="34.69"/>
                    <measurement group_id="O3" value="-18" spread="34.87"/>
                    <measurement group_id="O4" value="-32.6" spread="31.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Target Lesion Score at Week 4 Compared to Baseline</title>
        <description>Change in score from 0-14 of target lesion disease activity based on scaling, erythema, and induration as determined by a physician assessor at week 4 compared to baseline (with 0 being no disease activity and 14 being maximum disease activity).</description>
        <time_frame>Baseline to week 4</time_frame>
        <population>all 5 patients per cohort completed the visit at week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, 10 ug/ml Fluphenazine Treated Lesion</title>
            <description>Cohort 1 10 ug/ml Fluphenazine decanoate treated lesion</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Placebo Treated Lesion</title>
            <description>Cohort 1 lesion treated with placebo</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2, 100 ug/ml Fluphenazine Treated Lesion</title>
            <description>Cohort 2 100 ug/ml Fluphenazine decanoate treated lesion</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Placebo Treated Lesion</title>
            <description>Cohort 2 lesion treated with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Target Lesion Score at Week 4 Compared to Baseline</title>
          <description>Change in score from 0-14 of target lesion disease activity based on scaling, erythema, and induration as determined by a physician assessor at week 4 compared to baseline (with 0 being no disease activity and 14 being maximum disease activity).</description>
          <population>all 5 patients per cohort completed the visit at week 4</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2.45"/>
                    <measurement group_id="O2" value="-0.8" spread="2.68"/>
                    <measurement group_id="O3" value="-0.4" spread="2.19"/>
                    <measurement group_id="O4" value="-1.5" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: 10 ug/ml Fluphenazine Decanoate</title>
          <description>Receiving fluphenazine decanoate (10 ug/ml) in a target lesion on one side of the body and placebo in a lesion on the other side of the body</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: 100 ug/ml Fluphenazine Decanoate</title>
          <description>Receiving fluphenazine decanoate (100 ug/ml) in a target lesion on one side of the body and placebo in a lesion on the other side of the body</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>contact lens irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cold/sinus symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>local reaction, occurred in both fluphenazine treated and placebo treated lesions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>tired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>contact dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>itchy lesions</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>local reaction. In both cohort 1 patients, occurred in both fluphenazine treated and placebo treated lesions.
In the cohort 2 patient, occurred in only fluphenazine treated lesion.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>lesion pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>local reaction, occurred in only fluphenazine treated lesion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>psoriatic lesion spreading</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>local reaction, occurred in both fluphenazine treated and placebo treated lesions in addition to other non target lesions.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>sunburn (1st degree)</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>local reaction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alice B Gottlieb, MD, PhD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617 636 4802</phone>
      <email>agottlieb@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

